Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Medical Oncology Associates
mi
from
Kingston, PA
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Medical Oncology Associates
mi
from
Kingston, PA
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center-Abilene (South)
mi
from
Abilene, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center-Abilene (South)
mi
from
Abilene, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. -Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center
mi
from
Arlington, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center
mi
from
Arlington, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center At Medical City
mi
from
Dallas, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center At Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Onclogy, P.A.
mi
from
Dallas, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Onclogy, P.A.
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center
mi
from
Denton, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center
mi
from
Denton, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Allison Cancer Center
mi
from
Midland, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Odessa
mi
from
Odessa, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Odessa
mi
from
Odessa, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
HOAST-Medical Dr.
mi
from
San Antonio, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
HOAST-Medical Dr.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Care and Research
mi
from
Waco, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Care and Research
mi
from
Waco, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A.
mi
from
Webster, TX
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A.
mi
from
Webster, TX
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Onc and Hem Associates of SW VA, Inc.
mi
from
Salem, VA
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Onc and Hem Associates of SW VA, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Puget Sound Cancer Center - Edmonds
mi
from
Edmonds, WA
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Puget Sound Cancer Center - Edmonds
mi
from
Edmonds, WA
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Puget Sound Cancer Center - Seattle
mi
from
Seattle, WA
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Puget Sound Cancer Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists-Vancouver
mi
from
Vancouver, WA
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists-Vancouver
mi
from
Vancouver, WA
Click here to add this to my saved trials
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Phase II Sunitinib Prog Met AIPC
Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Phase II Study of Radiofrequency Ablation of Colorectal Cancer Liver Metastases Combined With Post-Ablation Hepatic Arterial Infusion of Floxuridine Alternating With 5-Fluorouracil
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Phase II Study of Radiofrequency Ablation of Colorectal Cancer Liver Metastases Combined With Post-Ablation Hepatic Arterial Infusion of Floxuridine Alternating With 5-Fluorouracil
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  12/31/1969
Hematology-Oncology Associates of Illinois
mi
from
Chicago, IL
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 12/31/1969
Hematology-Oncology Associates of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  12/31/1969
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 12/31/1969
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
A Phase 1 Trial of PSA-Activated PSA-PAH1 Therapy for Locally Recurrent Prostate Cancer Without Metastases After Primary Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
Cancer Research Institute of Scott and White
mi
from
Temple, TX
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
A Phase 1 Trial of PSA-Activated PSA-PAH1 Therapy for Locally Recurrent Prostate Cancer Without Metastases After Primary Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
Cancer Research Institute of Scott and White
mi
from
Temple, TX
Click here to add this to my saved trials
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy
Status: Enrolling
Updated:  12/31/1969
The University of Texas M. D. Anderson Cancer Center
mi
from
Houston, TX
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy
Status: Enrolling
Updated: 12/31/1969
The University of Texas M. D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Randomized Double-blind Placebo-controlled Trial of Primary Prophylaxis With Recombinant Human Thrombopoietin Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Randomized Double-blind Placebo-controlled Trial of Primary Prophylaxis With Recombinant Human Thrombopoietin Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
High Dose I-131 Metaiodobenzylguanidine (MIBG) Therapy for Metastatic Neuroendocrine Tumors
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
High Dose I-131 Metaiodobenzylguanidine (MIBG) Therapy for Metastatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
Phase I/II Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma (AI-PCa)
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
Phase I/II Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma (AI-PCa)
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
Dose Finding Study of Gelonin Purging of Autologous Stem Cells for Transplantation of Patients With AML/MDS in First or Subsequent Remission
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
Dose Finding Study of Gelonin Purging of Autologous Stem Cells for Transplantation of Patients With AML/MDS in First or Subsequent Remission
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Fort Smith, AR
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Atlanta Regional
mi
from
Atlanta, GA
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Atlanta Regional
mi
from
Atlanta, GA
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials